Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

163 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation.
Brown BP, Zhang YK, Westover D, Yan Y, Qiao H, Huang V, Du Z, Smith JA, Ross JS, Miller VA, Ali S, Bazhenova L, Schrock AB, Meiler J, Lovly CM. Brown BP, et al. Clin Cancer Res. 2019 Jun 1;25(11):3341-3351. doi: 10.1158/1078-0432.CCR-18-3829. Epub 2019 Feb 22. Clin Cancer Res. 2019. PMID: 30796031 Free PMC article.
Lipocalin Blc is a potential heme-binding protein.
Bozhanova NG, Calcutt MW, Beavers WN, Brown BP, Skaar EP, Meiler J. Bozhanova NG, et al. Among authors: brown bp. FEBS Lett. 2021 Jan;595(2):206-219. doi: 10.1002/1873-3468.14001. Epub 2020 Dec 3. FEBS Lett. 2021. PMID: 33210733 Free PMC article.
Structure-function analysis of oncogenic EGFR Kinase Domain Duplication reveals insights into activation and a potential approach for therapeutic targeting.
Du Z, Brown BP, Kim S, Ferguson D, Pavlick DC, Jayakumaran G, Benayed R, Gallant JN, Zhang YK, Yan Y, Red-Brewer M, Ali SM, Schrock AB, Zehir A, Ladanyi M, Smith AW, Meiler J, Lovly CM. Du Z, et al. Among authors: brown bp. Nat Commun. 2021 Mar 2;12(1):1382. doi: 10.1038/s41467-021-21613-6. Nat Commun. 2021. PMID: 33654076 Free PMC article.
Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity.
Hanker AB, Brown BP, Meiler J, Marín A, Jayanthan HS, Ye D, Lin CC, Akamatsu H, Lee KM, Chatterjee S, Sudhan DR, Servetto A, Brewer MR, Koch JP, Sheehan JH, He J, Lalani AS, Arteaga CL. Hanker AB, et al. Among authors: brown bp. Cancer Cell. 2021 Aug 9;39(8):1099-1114.e8. doi: 10.1016/j.ccell.2021.06.001. Epub 2021 Jun 24. Cancer Cell. 2021. PMID: 34171264 Free PMC article.
163 results